NRC — Cell Culture Pilot Plant

Bringing a biologic or vaccine from the lab into pilot-scale production is a major hurdle for many life sciences companies, especially when in-house bioprocessing infrastructure is limited. For Canadian biotechnology firms working with mammalian cell expression systems, the NRC — Cell Culture Pilot Plant offers access to advanced facilities and hands-on expertise to help bridge that gap between early development and manufacturing readiness.

Delivered by the National Research Council of Canada through its Human Health Therapeutics Research Centre, this national, fee-for-service program supports process development and scale-up using CHO, HEK293, and other animal cell lines. Companies can work directly with experienced cell biologists, biochemical engineers, and purification specialists on activities such as optimizing culture media, refining feeding strategies, scaling batch or perfusion processes, and developing in‑process assays. The pilot plant is equipped to support bioreactor work from bench scale through to pilot volumes of up to 500 litres, allowing businesses to generate high-quality material for preclinical studies or manufacturing transfer.

The program is well suited to startups, growing SMEs, and established enterprises developing recombinant proteins, viral vectors, or vaccines, particularly those preparing for technology transfer to a contract manufacturing organization. Costs vary depending on project scope, but the value lies in access to specialized infrastructure and NRC expertise without the need for long-term capital investment. For biotech companies navigating scale-up challenges, learning more about how this pilot plant operates can clarify whether it fits into your development and commercialization plans.